| Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) B Hanfstein, MC Müller, R Hehlmann, P Erben, M Lauseker, A Fabarius, ... Leukemia 26 (9), 2096-2102, 2012 | 512 | 2012 |
| Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-a in newly diagnosed chronic myeloid leukemia R Hehlmann, M Lauseker, S Jung-Munkwitz, A Leitner, MC Müller, ... J Clin Oncol 29 (12), 1634-1642, 2011 | 416 | 2011 |
| Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV A Fabarius, A Leitner, A Hochhaus, MC Müller, B Hanfstein, C Haferlach, ... Blood, The Journal of the American Society of Hematology 118 (26), 6760-6768, 2011 | 353 | 2011 |
| Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results … R Hehlmann, MC Müller, M Lauseker, B Hanfstein, A Fabarius, ... J Clin Oncol 32 (5), 415-423, 2014 | 338 | 2014 |
| Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants R Hehlmann, M Lauseker, S Saußele, M Pfirrmann, S Krause, HJ Kolb, ... Leukemia 31 (11), 2398-2406, 2017 | 321 | 2017 |
| Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV L Kalmanti, S Saußele, M Lauseker, MC Müller, CT Dietz, L Heinrich, ... Leukemia 29 (5), 1123-1132, 2015 | 307 | 2015 |
| Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized … S Saussele, M Lauseker, A Gratwohl, DW Beelen, D Bunjes, ... Blood, The Journal of the American Society of Hematology 115 (10), 1880-1885, 2010 | 307 | 2010 |
| Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV S Saußele, MP Krauss, R Hehlmann, M Lauseker, U Proetel, L Kalmanti, ... Blood, The Journal of the American Society of Hematology 126 (1), 42-49, 2015 | 194 | 2015 |
| Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann, S Saussele, C Dietz, ... Leukemia 28 (10), 1988-1992, 2014 | 163 | 2014 |
| Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del (5q): a multicenter study U Germing, M Lauseker, B Hildebrandt, A Symeonidis, J Cermak, ... Leukemia 26 (6), 1286-1292, 2012 | 152 | 2012 |
| Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib B Hanfstein, M Lauseker, R Hehlmann, S Saussele, P Erben, C Dietz, ... haematologica 99 (9), 1441-1447, 2014 | 141 | 2014 |
| Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study J Neukirchen, M Lauseker, S Blum, A Giagounidis, M Lübbert, S Martino, ... Leukemia research 38 (1), 57-64, 2014 | 93 | 2014 |
| Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV MB Miranda, M Lauseker, MP Kraus, U Proetel, B Hanfstein, A Fabarius, ... Leukemia 30 (6), 1255-1262, 2016 | 87 | 2016 |
| Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low-or Intermediate-1-risk MDS with del (5q): a comparative analysis A Kuendgen, M Lauseker, AF List, P Fenaux, AA Giagounidis, ... Leukemia 27 (5), 1072-1079, 2013 | 87 | 2013 |
| Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML A Fabarius, L Kalmanti, CT Dietz, M Lauseker, S Rinaldetti, C Haferlach, ... Annals of hematology 94 (12), 2015 | 84 | 2015 |
| CCL1 is a major regulatory T cell attracting factor in human breast cancer B Kuehnemuth, I Piseddu, GM Wiedemann, M Lauseker, C Kuhn, ... BMC cancer 18 (1), 1-6, 2018 | 80 | 2018 |
| Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV L Kalmanti, S Saussele, M Lauseker, U Proetel, MC Müller, B Hanfstein, ... Annals of hematology 93 (1), 71-80, 2014 | 77 | 2014 |
| Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia M Pfirrmann, A Hochhaus, M Lauseker, S Saußele, R Hehlmann, ... Leukemia 25 (9), 1433-1438, 2011 | 74 | 2011 |
| Efficacy of azacitidine is independent of molecular and clinical characteristics-an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a … A Kuendgen, C Müller-Thomas, M Lauseker, T Haferlach, P Urbaniak, ... Oncotarget 9 (45), 27882, 2018 | 72 | 2018 |
| Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary … T Schroeder, N Wegener, M Lauseker, C Rautenberg, K Nachtkamp, ... Biology of Blood and Marrow Transplantation 25 (8), 1550-1559, 2019 | 65 | 2019 |
